Adalimumab - us licensed humira (DrugBank: Adalimumab)
16 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 0 |
37 | 膿疱性乾癬(汎発型) | 0 |
40 | 高安動脈炎 | 0 |
41 | 巨細胞性動脈炎 | 0 |
46 | 悪性関節リウマチ | 1 |
56 | ベーチェット病 | 0 |
84 | サルコイドーシス | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
151 | ラスムッセン脳炎 | 0 |
160 | 先天性魚鱗癬 | 0 |
164 | 眼皮膚白皮症 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
269 | 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 | 0 |
271 | 強直性脊椎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02744755 (ClinicalTrials.gov) | March 31, 2016 | 12/4/2016 | Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis | A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: Adalimumab - GP2017;Biological: Adalimumab - US licensed Humira | Sandoz | Hexal AG | Completed | 18 Years | N/A | All | 353 | Phase 3 | United States;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;Czech Republic |